患有子宫内膜异位症相关症状的女性可能会受益于水飞蓟素,一种抗氧化剂

Amna Faheem Mufti, Abdul Wahid Rizwan, Hassan Farooq
{"title":"患有子宫内膜异位症相关症状的女性可能会受益于水飞蓟素,一种抗氧化剂","authors":"Amna Faheem Mufti, Abdul Wahid Rizwan, Hassan Farooq","doi":"10.47391/jpma.9669","DOIUrl":null,"url":null,"abstract":"Madam, Endometriosis is a potentially debilitating disease in which endometrial tissue is present outside the uterine cavity. It can be symptomless in some women, while causing severe pelvic pain, dysmenorrhea, dyspareunia, and decreased fertility in others.1 According to the World Health Organisation (WHO), endometriosis affects 10% (190 million) of reproductive age women globally.2 Endometriomas are the most common manifestation of endometriosis on the ovary, indicating a more severe disease state.3 In October 2022, a randomised trial was conducted to study Silymarin's efficacy on endometrioma-related manifestations. 4 The trial was the first of its kind. It showed that Silymarin, a herbal supplement with potent antioxidant effects, significantly decrease endometrioma size and the chronic pelvic pain related to it.4 Oxidative Stress, an imbalance between ROS and antioxidants, is known as a primary factor in the endometriosis pathogenesis5, and Silymarin may be ten times as potent as Vitamin E, another antioxidant which has been investigated in relation to endometriosis treatment.4 In Pakistan, the estimated prevalence of endometriosis is 16.8%6, which means a significant number of women are living with the manifestations that come with the disease, including endometriomas, which are seen in 17 to 44% of individuals with endometriosis.3 Silymarin is already available and used in Pakistan for its hepatoprotective effects. In light of this, it is of great importance that this new treatment and its effects are studied on a larger scale, specifically on the Pakistani population to learn more about its potential in reducing the suffering and improving the quality of life of these women.","PeriodicalId":16673,"journal":{"name":"Journal of Pakistan Medical Association","volume":"22 2","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Women suffering from endometrioma-related symptoms may benefit from Silymarin, an antioxidant\",\"authors\":\"Amna Faheem Mufti, Abdul Wahid Rizwan, Hassan Farooq\",\"doi\":\"10.47391/jpma.9669\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Madam, Endometriosis is a potentially debilitating disease in which endometrial tissue is present outside the uterine cavity. It can be symptomless in some women, while causing severe pelvic pain, dysmenorrhea, dyspareunia, and decreased fertility in others.1 According to the World Health Organisation (WHO), endometriosis affects 10% (190 million) of reproductive age women globally.2 Endometriomas are the most common manifestation of endometriosis on the ovary, indicating a more severe disease state.3 In October 2022, a randomised trial was conducted to study Silymarin's efficacy on endometrioma-related manifestations. 4 The trial was the first of its kind. It showed that Silymarin, a herbal supplement with potent antioxidant effects, significantly decrease endometrioma size and the chronic pelvic pain related to it.4 Oxidative Stress, an imbalance between ROS and antioxidants, is known as a primary factor in the endometriosis pathogenesis5, and Silymarin may be ten times as potent as Vitamin E, another antioxidant which has been investigated in relation to endometriosis treatment.4 In Pakistan, the estimated prevalence of endometriosis is 16.8%6, which means a significant number of women are living with the manifestations that come with the disease, including endometriomas, which are seen in 17 to 44% of individuals with endometriosis.3 Silymarin is already available and used in Pakistan for its hepatoprotective effects. In light of this, it is of great importance that this new treatment and its effects are studied on a larger scale, specifically on the Pakistani population to learn more about its potential in reducing the suffering and improving the quality of life of these women.\",\"PeriodicalId\":16673,\"journal\":{\"name\":\"Journal of Pakistan Medical Association\",\"volume\":\"22 2\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pakistan Medical Association\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47391/jpma.9669\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pakistan Medical Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47391/jpma.9669","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

女士,子宫内膜异位症是一种潜在的衰弱性疾病子宫内膜组织出现在子宫腔外。一些妇女可能没有症状,而另一些妇女则会引起严重的盆腔疼痛、痛经、性交困难和生育能力下降根据世界卫生组织(WHO)的数据,子宫内膜异位症影响着全球10%(1.9亿)的育龄妇女子宫内膜异位症是卵巢子宫内膜异位症最常见的表现,预示着更严重的疾病状态2022年10月,进行了一项随机试验,研究水飞蓟素对子宫内膜异位症相关表现的疗效。这是第一次这样的试验。研究表明,水飞蓟素,一种具有强抗氧化作用的草药补充剂,可以显著减少子宫内膜瘤的大小和与之相关的慢性盆腔疼痛氧化应激,ROS和抗氧化剂之间的不平衡,被认为是子宫内膜异位症发病的主要因素,水飞蓟素的效力可能是维生素E的十倍,维生素E是另一种抗氧化剂,已被研究与子宫内膜异位症的治疗有关在巴基斯坦,子宫内膜异位症的患病率估计为16.8%6,这意味着相当多的妇女患有该疾病带来的症状,包括子宫内膜异位症,子宫内膜异位症患者中有17%至44%患有子宫内膜异位症3水飞蓟素在巴基斯坦已经有了保护肝脏的功效。有鉴于此,对这种新的治疗方法及其效果进行更大规模的研究,特别是对巴基斯坦人口进行研究,以更多地了解其在减少这些妇女的痛苦和改善其生活质量方面的潜力,这一点非常重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Women suffering from endometrioma-related symptoms may benefit from Silymarin, an antioxidant
Madam, Endometriosis is a potentially debilitating disease in which endometrial tissue is present outside the uterine cavity. It can be symptomless in some women, while causing severe pelvic pain, dysmenorrhea, dyspareunia, and decreased fertility in others.1 According to the World Health Organisation (WHO), endometriosis affects 10% (190 million) of reproductive age women globally.2 Endometriomas are the most common manifestation of endometriosis on the ovary, indicating a more severe disease state.3 In October 2022, a randomised trial was conducted to study Silymarin's efficacy on endometrioma-related manifestations. 4 The trial was the first of its kind. It showed that Silymarin, a herbal supplement with potent antioxidant effects, significantly decrease endometrioma size and the chronic pelvic pain related to it.4 Oxidative Stress, an imbalance between ROS and antioxidants, is known as a primary factor in the endometriosis pathogenesis5, and Silymarin may be ten times as potent as Vitamin E, another antioxidant which has been investigated in relation to endometriosis treatment.4 In Pakistan, the estimated prevalence of endometriosis is 16.8%6, which means a significant number of women are living with the manifestations that come with the disease, including endometriomas, which are seen in 17 to 44% of individuals with endometriosis.3 Silymarin is already available and used in Pakistan for its hepatoprotective effects. In light of this, it is of great importance that this new treatment and its effects are studied on a larger scale, specifically on the Pakistani population to learn more about its potential in reducing the suffering and improving the quality of life of these women.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Impact of haemodialysis on plasma carnitine concentrations in haemodialysis patients Surgical-orthodontic with atypical extraction pattern as a treatment for an anterior open bite: a case report Association between hip flexor tightness and lumbar instability in adults Utilization of the complete blood count in diagnosing endemic diseases in Pakistan Is a Therapeutic approach required to treat Insomnia in Pakistan?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1